Graft Polymer PLC has applied for a standard listing on the London Stock Exchange.
Headquartered in in London, Graft said it will use funds raised through the IPO to accelerate the development of its polymer modification technology, where it already supplies its IP for use in healthcare, manufacturing and fire protection.
Last year, the group launched a new division developing Bio/Pharma applications.
In 2020, the global impact modifier market was estimated to have a value of $3.9 billion.
Victor Bolduev, founder and chief executive, said: "We are delighted to be bringing Graft Polymer to the London Stock Exchange's Main Market, particularly at a time when demand for combining polymer modification and environmental protection is rising.
“Graft Polymer's IPO will provide the company with further capital to accelerate our developing of intellectual property as well as new technologies to provide novel products and solutions for market challenges that arise.”